Overview

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.
Phase:
Phase 2
Details
Lead Sponsor:
Atrium Health
Carolinas Healthcare System
Collaborator:
Professional Compounding Centers of America